Mai Elzahry, Waleed Diab and Helmut Sinzinger
Background: Sm-153 EDTMP is a widely accessible radiopharmaceutical for systemic radionuclide therapy in cancer patients with painful skeletal disseminations; its use is expressed to any metastatic bone lesions which has been avid to Tc-99m MDP. In this study we obtained a clinical experience with a single therapeutic dose of Sm-153 EDTMP on cancer patients showed painless bone metastases on conventional bone scintigraphy, its bone response so far has not been studied in a large number of patients. Objective: evaluation of the overall therapeutic bone response in 103 cancer patients showed a painless skeletal metastases whom underwent a single therapeutic dose of Sm-153 EDTMP and elaborate if there is a significant difference in bone response depending on gender, patients age, pathology of primary cancer, number of the metastatic bone lesions. Methods: 103 patients were included in this retrospective analysis, 78(75.7%) males and 25(24.3%) females, their age range (19-92y, mea= ± SD=64.3 ± 13.7), their diagnosis were prostate (60.2%), breast(19.4%), lung(7.8%), other primaries(12.6%), 64.1% of cancer patients showed less than 10 bone lesions, 35.9% showed more than 10 bone lesions on conventional bone scintigraphy performed pretherapy. Results: Out of 103 cancer patients received a single dose of Sm- 153 EDTMP therapy, 67% (69/103) showed overall therapeutic bone stabilization/regression and 33% (34/103) showed bone progression, the rate of bone progression/regression showed a statistical significant difference among cancer patients dependent on their gender, age, type of cancer (P-values<0.005), while the rate of bone progression/stabilization differed significantly among those with more than 10 bone lesions as compared with patients showed less than 10 bone lesions on conventional bone scintigraphy. Conclusion: This study showed that as Sm-153 EDTMP offers a riskless and effective therapy options in patients with painful bone disseminations, it also provides encouraging results among those with painless skeletal metastases.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi